

B1  
Cmt crystalline calcium phosphates and a physiologically acceptable fluid, the paste having an injectable or formable consistency at the time of administration and hardenable at the tumor site.

---

Bal 24. (Twice Amended) The composition of claim 22, wherein the anticancer agent is selected from the group consisting of methotrexate, cisplatin, prednisone, hydroxyprogesterone, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, testosterone propionate, fluoxymesterone, vinblastine, vincristine, vindesine, daunorubicin, doxorubicin, hydroxyurea, procarbazine, aminoglutethimide, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, busulfan, carmustine, lomustine, dacarbazine (DTIC, dimethyltriazenomideazolecarboxamide), procarbozine, 5-fluorouracil, cytarabine, cytosine arabinoside, 6-mercaptopurine, tamoxifen, paclitaxel, etoposide, vinorelbine, gemcitabine, leuprolide, flutamide, goserelin acetate, thioguanine, and their derivatives and mixtures thereof.

---

B3 40. (Amended) The composition of claim 22, wherein delivery of the anticancer therapy to the tumor site is sufficient to promote a decrease in tumor mass without significant weight loss in the mammal.

---

B4 42. (Amended) A kit for use in preparing a flowable anticancer composition that remains injectable for at least about 20 minutes, said kit comprising:

- (a) dry ingredients comprising a nanocrystalline or poorly crystalline calcium phosphate and a second calcium phosphate in a proportion of about 1:10 to 10:1 by weight;
- (b) a physiologically acceptable aqueous lubricant in an amount sufficient to produce a

BY  
CMT  
flowable product upon combination with said dry ingredients; and

(c) an anticancer agent in an amount ranging from about 0.01 to 10 wt. % of said dry ingredients.

---